Published in Cancer Weekly, February 20th, 2007
The company showed clear success in the planned transition to its recurring revenue per procedure business.
For fiscal year 2006, total revenues are estimated at EUR 20 million ($26 million). For the full year, RPP revenues increased by approximately 60% to more than EUR 2.8 million in response to market growth and the company's new marketing and education initiatives launched in the second half. Service and disposable revenue increased to more than EUR 2.2 million. Sales include revenue from 8 Ablatherm and 37 ESWL devices during the period. At...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.